Introduction {#sec1-1}
============

Primary ductal adenocarcinoma of lacrimal gland is a distinct subtype of lacrimal gland adenocarcinoma, accounting for only 2% of all epithelial lacrimal gland tumors.\[[@ref1]\] There are only some sporadic cases reported in the literature. Primary ductal adenocarcinoma of lacrimal gland is generally thought to be an aggressive malignancy; however, their clinical features, treatment, and outcome remained not well understood. In this study, we report two cases of adenocarcinoma of the lacrimal gland with a review of the literature.

Case Reports {#sec1-2}
============

Case 1 {#sec2-1}
------

A 64-year-old male presented with progressive proptosis of the left eye for 3 months \[[Figure 1a](#F1){ref-type="fig"}\]. He denied any systemic disease or surgical history before. On examination, the best-corrected visual acuity was 6/6 in both eyes. There was 5 mm of proptosis in the left eye compared with the right eye. Eye movement was limited in the upper gaze of the left eye. Other ophthalmic examination results were unremarkable. Orbital computed tomography (CT) revealed a 3.9 cm × 2.2 cm × 3.7 cm lobulated mass with lateral orbital wall erosion \[Figure [1b](#F1){ref-type="fig"} and [c](#F1){ref-type="fig"}\]. Laboratory survey showed no significant findings. He underwent incisional biopsy, and histopathological examination revealed an infiltrative tumor composed of tumor cells with eosinophilic cytoplasm and prominent nucleoli arranged in an irregular glandular pattern. The tumor cells were immunoreactive for androgen receptor (AR) and cytokeratin-7 (CK7). Immunostains for cytokeratin-20 (CK20), thyroid transcription factor-1 (TTF-1), and prostatic-specific antigen were negative. The above findings are compatible with primary ductal adenocarcinoma of lacrimal gland. Whole-body positron emission tomography (PET)-CT showed no evidence of systemic involvement. He then underwent an orbital exenteration which the gross examination revealed a white firm tumor measuring 3.5 cm × 8 cm × 5 cm \[[Figure 1d](#F1){ref-type="fig"}\]. The tumor was composed of nests of cuboidal and columnar cells with eosinophilic cytoplasm and vesicular nuclei and occasional mitosis. The tumor cells were arranged in ductal structures of varying sizes, allying with cribriform pattern \[[Figure 1e](#F1){ref-type="fig"}\]. Mucin secretion was seen in some ductal lumens. Lymphovascular emboli and perineural invasion were also found. Immunohistochemical stains for CK7 \[[Figure 1f](#F1){ref-type="fig"}\], AR, and gross cystic disease fluid protein 15 (GCDFP-15) were positive. The final diagnosis was primary ductal adenocarcinoma of lacrimal gland, staging T4N0M0. The patient subsequently received adjuvant chemoradiotherapy. He took the radiation dose of 6800cGy in 34 fractions at superior and lateral surgical bed, 6120cGy in 34 fractions at the other surgical bed, and 5780cGy in 34 fractions at the left parotid gland and neck lymph node. At the same time, he received cisplatin and tegafur-uracil weekly for seven cycles as chemotherapy. There was no evidence of recurrence or metastasis 27 months after treatment.

![(a) Case 1 presented with proptosis and inferior displacement of the left globe. (b and c) Axial and coronal orbital computed tomography demonstrates a tumor about 3.9 cm × 2.2 cm × 3.7 cm in size in the superotemporal orbit. (d) Gross pathology of the excised specimen and tumor marked with stars. (e) Microscopic findings reveal ductal structures with abundant granular eosinophilic cytoplasm (H and E, ×100). (f) Immunostain shows strong expression of androgen receptor (×100)](TJO-8-42-g001){#F1}

Case 2 {#sec2-2}
------

A 64-year-old male presented with proptosis of the right eye and diplopia for 3 weeks \[[Figure 2a](#F2){ref-type="fig"}\]. On ophthalmic examination, best-corrected visual acuity was 6/20 in the right eye and 6/8.6 in the left eye. Ocular movement showed limited abduction of the right eye. Hertel exophthalmometry showed 5 mm of proptosis of the right eye compared with the left eye. Other ophthalmic examination results were unremarkable. Orbital CT showed a mass lesion about 5 cm × 5 cm × 3.3 cm in the right lateral orbital with extensive bony destruction and extension to deep temporal fossa \[Figure [2b](#F2){ref-type="fig"}--[d](#F2){ref-type="fig"}\]. The patient underwent orbital biopsy which revealed primary ductal adenocarcinoma of lacrimal gland. Immunohistochemical stain showed positive for CK7, AR, and epidermal growth factor receptor (EGFR) but negative for CK20 and TTF-1. Whole-body PET-CT showed no evidence of systemic involvement. Then, he underwent radical surgery with orbital exenteration and removal of adjacent lateral and inferior orbital wall and reconstruction with metal plate and free myocutaneous flap. Histological studies showed an infiltrative tumor composed of pleomorphic tumor glands, which resemble high-grade ductal carcinoma *in situ* and infiltrating carcinoma of the breast. The tumor cells have eosinophilic cytoplasm, enlarged nuclei, and prominent nucleoli \[[Figure 2e](#F2){ref-type="fig"}\]. There is also a hyalinized nodule in the center of the tumor. Bony, perineural, and lymphovascular invasion was noted. Immunohistochemically, the tumor is positive for AR \[[Figure 2f](#F2){ref-type="fig"}\]. The patient then underwent concomitant chemoradiotherapy. He received six cycles of cisplatin and tegafur-uracil weekly and radiotherapy with 6600cGy in 33 fractions at surgical bed and 5040cGy in 28 fractions at the right orbital flap. However, distant metastasis to neck lymph nodes and bilateral upper lobes of the lung was noted at the 21^st^ month of follow-up. Total parotidectomy of the right parotid gland and modified radical neck dissection were performed. The patient refused further chemoradiotherapy and lost to follow-up.

![(a) Case 2 manifested as proptosis and inferior displacement of the right globe. (b-d) Axial and coronal orbital computed tomography demonstrates an infiltrated tumor mass in the lateral orbit of the right eye and destruction of lateral and inferior orbital wall with extension to deep temporal fossa. Focal calcification in the tumor is noted. (e) Microscopic findings revealed ductal structure with comedo necrosis (H and E, ×100). (f) Immunostain shows positive nuclear expression for androgen receptor (×100)](TJO-8-42-g002){#F2}

Discussion {#sec1-3}
==========

Primary ductal adenocarcinoma of lacrimal gland was first reported by Katz *et al*. in 1996.\[[@ref2]\] The pathological characteristics are similar to salivary duct carcinomas and ductal carcinomas of the breast. The clinical features and treatment outcome were not well constructed because sparse cases were reported.

We retrospectively review 24 collected and our 2 new cases of primary ductal adenocarcinomas of lacrimal gland in the literature \[[Table 1](#T1){ref-type="table"}\].\[[@ref3][@ref4][@ref5][@ref6][@ref7][@ref8][@ref9][@ref10][@ref11][@ref12][@ref13][@ref14][@ref15][@ref16][@ref17][@ref18][@ref19][@ref20]\] The mean age of the 26 patients was 57 years old and most cases were males (73%). Two of them had pleomorphic adenoma at the same location\[[@ref4][@ref13]\] and one had a history of neurofibromatosis.\[[@ref18]\] The most common presenting symptom was exophthalmos. The typical appearance of this tumor in orbital CT showed irregular shape lesion with focal destructive change at lacrimal gland area. Adjacent extraocular muscle or bony invasion was not rare. Some cases also showed calcifications in CT image as in our case two.\[[@ref5][@ref11][@ref17]\] Early diagnosis is crucial because the tumor was pretty aggressive because these patients had a mean tumor size of 3 cm in diameter (ranges from 1.1 to 5 cm) at initial examination, and metastasis was seen during follow-up in 15 patients (58%). The diagnosis was confirmed by pathological analysis, and the typical appearance of the tumor is ductal structure with abundant granular eosinophilic cytoplasm. Comedo necrosis in the duct may present. Immunohistological examinations of primary ductal adenocarcinoma of lacrimal gland often showed positive to AR (46%), CK7 (46%), Ki-67 (38%), GCDFP-15 (35%), human EGFR-2 (Her-2) (35%), and p53 (35%), which are similar to salivary duct carcinomas and ductal carcinomas of the breast. It is reported that salivary duct carcinomas showed 93% positive result of AR while 1% and 6% in estrogen receptor (ER) and progesterone receptor (PR), respectively.\[[@ref21]\] Breast cancer showed more than 50% positive rate of ER and PR.\[[@ref22]\] According to the immunohistological finding of ductal adenocarcinomas of lacrimal gland, positive expression of AR while negative of ER and PR may indicate that the biological character of the tumor was more similar to salivary duct carcinomas. Clinically, aggressive presentation of salivary duct carcinomas is similar to primary ductal carcinomas of lacrimal gland as it was documented 46% of patients developed distant metastasis\[[@ref23]\] among the former while 15 patients (58%) showed the evidence of metastasis in our collected cases \[[Table 2](#T2){ref-type="table"}\]. Therefore, the treatment for primary ductal adenocarcinomas of lacrimal gland may refer to the treatment for salivary duct carcinomas as there are more documents of efficacy in the latter. Salivary duct carcinomas are mostly treated by surgery and possible radiochemical therapy according to staging. In addition, there were some reports that androgen deprivation therapy could be beneficial for patients with recurrent or disseminated disease.\[[@ref24]\] In our collected cases, Ricci *et al*.\[[@ref5]\] reported a case of primary ductal adenocarcinoma of lacrimal gland with L1 spine metastasis treated by total androgen blockage therapy, where the patient survived more than 10 months. Moreover, there are also some reports showing that with positive Her-2, a proto-oncogene which is overexpressed in salivary duct carcinomas and breast ductal carcinomas, the patients treated with monoclonal antibody against EGFR such as trastuzumab may improve prognosis in both salivary duct carcinomas\[[@ref25]\] and breast ductal carcinomas.\[[@ref26]\] Dennie\[[@ref7]\] reported a case of primary ductal adenocarcinoma of lacrimal gland who was treated with lapatinib, an oral tyrosine kinase inhibitor against Her-2 and EGFR, survived 4 years after diagnosis. The efficacy of chemotherapy was uncertain as there are only two prior documented cases receiving adjuvant chemoradiotherapy in the literature besides our two cases. Giliberti *et al*.\[[@ref10]\] reported the patient received carboplatin, paclitaxel, and herceptin as chemotherapy after surgery. However, the clinical course after chemotherapy was not recorded. Kim *et al*.\[[@ref15]\] reported a case who died of disease 17 years after treatment with surgery and chemoradiotherapy, but regiment detail was not documented. Due to their rarity, the effectiveness of chemotherapy in primary ductal adenocarcinoma of lacrimal gland requires further investigation. Among the 26 collected cases, more than half of the patients received exenteration and/or adjunct radiotherapy and/or chemotherapy (58%). Even after aggressive treatment, nine patients (35%) died of disease, including one patient who died of disease 17 years after diagnosis. The cause of death was mostly distant metastasis including cervical lymph node (31%), brain (23%), bone (23%), lung (23%), and liver (15%). The reason why our two cases resulted in different prognosis may be that the tumor in the second case showed more extensive infiltration and bony destruction at initial diagnosis. Furthermore, the first case received additional prophylactic neck lymph node radiation after orbital exenteration, which was not performed in the second case. Prophylactic lymph node irradiation might benefit for locally advanced head-and-neck tumors.\[[@ref27]\]

###### 

Clinical features and immunohistological staining characteristics for 26 reported cases of primary ductal adenocarcinoma

  Literature                                Age      Sex                                              Symptoms                                                            Site    Maximum diameter (cm)                                                                  Immunostain (+)                                                          Immunostain (−)
  ----------------------------------------- -------- ------------------------------------------------ ------------------------------------------------------------------- ------- -------------------------------------------------------------------------------------- ------------------------------------------------------------------------ ---------------------------------------------
  Our case 1                                64       Male                                             Orbital mass and proptosis for 3 months                             Left    3.9                                                                                    AR, CK7, GCDFP-15                                                        CK20, TTF-1, PSA, S-100
  Our case 2                                64       Male                                             Proptosis and diplopia for 3 weeks                                  Right   5                                                                                      AR, CK7, EGFR                                                            CK20, TTF-1
  Andreasen *et al*. 2017\[[@ref9]\]        77       Male                                             Diplopia for 2 weeks                                                Left    3.2                                                                                    AR, CK7, CK17, CK19, Cyclin D1, EGFR, EMA, GCDFP-15, Her-2, p53, Ki-67   CEA, CK5/6, DOG1, ER, PR, PSA, S-100, α-SMA
  53                                        Male     Proptosis of the left eye for 5 years            Left                                                                2       CK5, CK6, CK7, CK19, Cyclin D1, EGFR, EMA, Her-2, p53, AR, CEA, CK17, GCDFP-15, Ki67   DOG1, ER, PR, PSA, S-100, α-SMA                                          
  73                                        Male     Proptosis for 5 years                            Right                                                               4       CK7, CK19, EGFR, EMA, Her-2, p53, CEA, CK17, Cyclin D1, GCDFP-15, Ki-67                AR, CK5/6, DOG1, ER, PR, PSA, S-100, α-SMA                               
  Dennie, 2015\[[@ref7]\]                   53       Female                                           Headache, blurred vision, and proptosis                             Right   3                                                                                      Keratin, CK7, mammaglobin                                                CK20, TTF-1, GCDFP-15, ER, PR
  Lau *et al*. 2015\[[@ref8]\]              34       Female                                           Right upper eyelid swelling for 1 year                              Right   2.8                                                                                    EMA, CD117, PAS                                                          S-100, CK20, Melan A
  Zhu *et al*. 2015\[[@ref3]\]              49       Female                                           Painless, palpable mass, double vision, and epiphora for 6 months   Left    1.1                                                                                    GCDFP-15, AR, Her-2, p53, Ki-67, CK18                                    ER, PR, P63, calponin, CD117
  Ricci *et al*. 2014\[[@ref5]\]            71       Male                                             Lumbar pain for 3 years and slight exophthalmos for several years   Right   2.3                                                                                    AR, GCDFP-15, CK7, Her-2                                                 TTF-1, PSA, ER, PR, CK20, CDX2
  Min *et al*. 2014\[[@ref6]\]              46       Male                                             Exophthalmos and blurred vision for 2 months                        Left    3                                                                                      CK5, CK7, CK20                                                           S-100, TTF-1, PSA
  Kubota *et al*. 2013\[[@ref11]\]          75       Male                                             Upper eyelid swelling for 3 months                                  Right   2.8                                                                                    AR, Her-2, p53, Ki-67                                                    ER, PR
  67                                        Male     Upper eyelid swelling and ptosis for 6 months    Left                                                                4       AR, p53, Ki-67                                                                         Her-2, ER, PR                                                            
  53                                        Male     Upper eyelid swelling and ptosis for 18 months   Right                                                               3.7     AR, p53, Ki-67                                                                         Her-2, ER, PR                                                            
  39                                        Male     Upper eyelid swelling for 6 months               Left                                                                2.5     AR, Her-2, p53, Ki-67                                                                  ER, PR                                                                   
  46                                        Female   Upper eyelid swelling for 1 months               Right                                                               2.5     AR, Her-2, p53, Ki-67                                                                  ER, PR                                                                   
  Damasceno and Holbach, 2012\[[@ref12]\]   78       Male                                             Diplopia, painless, palpable mass, and restricted abduction         Right   2.4                                                                                    CK7, MMP2, MMP9, MMP13, Her-2                                            CK5, CK20, p63, PSA, S100, TTF1
  Giliberti *et al*. 2011\[[@ref10]\]       17       Male                                             Right orbital mass for 6 months                                     Right   NA                                                                                     NA                                                                       NA
  Ishida *et al*. 2009\[[@ref13]\]          70       Female                                           Painful exophthalmos                                                Left    2.5                                                                                    GCDFP15, Ki-67                                                           AR, Her-2, ER, PR
  Lee and Oh, 2009\[[@ref14]\]              50       Male                                             Exophthalmos                                                        Right   4                                                                                      CK7, CK19, EMA                                                           Her-2, ER, PR, CK20, p53, S-100, α-SMA
  Kim *et al*. 2008\[[@ref15]\]             47       Male                                             Left lacrimal gland mass                                            Left    NA                                                                                     NA                                                                       NA
  Takahira *et al*. 2007\[[@ref4]\]         48       Female                                           Progressive exophthalmos for 3 years                                Left    3.8                                                                                    AR, GCDFP-15                                                             ER, PR
  Milman *et al*. 2005\[[@ref16]\]          59       Male                                             Orbital mass and blepharoptosis 15 years                            Right   1.5                                                                                    GCDFP-15, keratin AE1, CK7, CEA, EMA, CK20                               TTF-1, PSA, Her-2, ER, p53, S-100
  Kurisu *et al*. 2005\[[@ref17]\]          67       Male                                             Visual disturbance                                                  Right   3                                                                                      CK7, CK10, CK17, CK18, CK19                                              S-100, α-SMA, CK20
  Krishnakumar *et al*. 2003\[[@ref18]\]    46       Male                                             Firm irregular mass with progressive ptosis in the orbit 2 years    Left    NA                                                                                     NA                                                                       NA
  Paulino and Huvos, 1999\[[@ref19]\]       52       Female                                           NA                                                                  Right   NA                                                                                     NA                                                                       NA
  Nasu *et al*. 1998\[[@ref20]\]            67       Male                                             Small nodule in the upper eyelid                                    Right   2.5                                                                                    EMA, CK, CEA, S-100                                                      Actin, ER, PSA
  Katz *et al*. 1996\[[@ref2]\]             68       Male                                             Lump in the upper outer eyelid                                      Right   4                                                                                      Keratin                                                                  HMB-45, NSE, S-100, chromogranin, CEA, PSA

AR=Androgen receptor, CDX2=Caudal-type homeobox 2, CEA=Carcinoembryonic antigen, CK=Cytokeratin, EGFR=Epidermal growth factor receptor, EMA=Epithelial membrane antigen, ER=Estrogen receptor, GCDFP-15=Gross cystic disease fluid protein 15, Her-2=Human epidermal growth factor receptor 2, MMPs=Matrix metalloproteinases, NA=Not available, NSE=Neuronspecific enolase, PAS=Periodic acid--Schiff, PR=Progesterone receptor, PSA=Prostate-specific antigen, SMA=Smooth muscle actin, TTF-1=Thyroid transcription factor-1

###### 

Initial staging, treatment, and outcome for 26 reported cases of primary ductal adenocarcinoma

  Literature                                Initial staging                                       Treatment                                                                                                   Metastasis                                                                                      Outcome
  ----------------------------------------- ----------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- -------------------
  Our case 1                                T4N0M0                                                Exenteration, RT and CT                                                                                     Nil                                                                                             AOD at 2.25 years
  Our case 2                                T4N0M0                                                Exenteration with bone removal, RT, and CT                                                                  Right neck LN, lung                                                                             AWD at 1.75 years
  Andreasen *et al*. 2017\[[@ref9]\]        T4bN0M0                                               Exenteration and RT                                                                                         Nil                                                                                             DO at 1.6 years
  T1N0M1                                    Nil                                                   Lung, liver, suprarenal glands, vertebral column, cerebellum; LN of the neck, thorax, abdomen, and thorax   DWD at 5 years                                                                                  
  T4bN0M0                                   Tumor excision and RT                                 Disseminated disease                                                                                        DWD at 1.4 years                                                                                
  Dennie, 2015\[[@ref7]\]                   T4cN0M0                                               Exenteration, RT, and target therapy                                                                        Chest and thorax spine, cerebellum, lung                                                        DWD at 4 years
  Lau *et al*. 2015\[[@ref8]\]              T2N0M0                                                Tumor excision                                                                                              Nil                                                                                             AOD at 0.17 years
  Zhu *et al*. 2015\[[@ref3]\]              T1N0M0                                                Exenteration and RT                                                                                         Nil                                                                                             AOD at 0.75 years
  Ricci *et al*. 2014\[[@ref5]\]            T2NxM1                                                Exenteration, RT, and total androgen blockade                                                               L1 spine                                                                                        AWD at 1.6 years
  Min *et al*. 2014\[[@ref6]\]              T4bN0M0                                               Orbital mass removal and RT                                                                                 Nil                                                                                             AOD at 0.4 years
  Kubota *et al*. 2013\[[@ref11]\]          T4bN1M0                                               RT to ocular adnexa and surgical resection of submandibular LN                                              Cervical LN, lung                                                                               DWD at 2 years
  T2N0M0                                    Exenteration with bone removal                        Submandibular LN, bone, and liver                                                                           DWD at 1.3 years                                                                                
  T4aN0M0                                   Exenteration and RT                                   Spine, brain, liver                                                                                         DWD at 4.3 years                                                                                
  T4bN0M0                                   Exenteration with bone removal and RT                 Lung, brain                                                                                                 AWD at 10 years                                                                                 
  T2N0M0                                    Complete tumor resection with globe-sparing surgery   Nil                                                                                                         AOD at 5.5 years                                                                                
  Damasceno and Holbach, 2012\[[@ref12]\]   T2N0M0                                                Exenteration                                                                                                Ipsilateral parotid and cervical LN                                                             DWD at 2 years
  Giliberti *et al*. 2011\[[@ref10]\]       T4cN0M0                                               Exenteration                                                                                                Nil                                                                                             AOD at 0.5 years
  Ishida *et al*. 2009\[[@ref13]\]          T2NxMx                                                Tumor resection twice for recurrence and RT                                                                 NA                                                                                              AWD at 0.7 years
  Lee and Oh, 2009\[[@ref14]\]              T2N0M0                                                Tumor resection (en bloc) with globe-sparing surgery                                                        NA                                                                                              AOD at 0.8 years
  Kim *et al*. 2008\[[@ref15]\]             NA                                                    Exenteration, RT, and CT                                                                                    Chest skin, lymphatics, ilium, rib, femur, spine, orbit, postnasal region, Lspine, cerebellum   DWD at 17 years
  Takahira *et al*. 2007\[[@ref4]\]         T2N0M0                                                Total tumor excision and RT                                                                                 Nil                                                                                             NA
  Milman *et al*. 2005\[[@ref16]\]          T1N1M1                                                Exenteration and RT                                                                                         Parotid, cervical LN                                                                            AWD at 0.5 years
  Kurisu *et al*. 2005\[[@ref17]\]          T2N0M0                                                En bloc tumor resection and RT                                                                              Local recurrence; brain, lungs, liver, pancreas, common bile duct                               DWD at 2.8 years
  Krishnakumar *et al*. 2003\[[@ref18]\]    NA                                                    Exenteration and RT                                                                                         Nil                                                                                             AOD at 1.6 years
  Paulino and Huvos, 1999\[[@ref19]\]       Parotid                                               Exenteration and RT                                                                                         Neck LN                                                                                         AOD at 6 years
  Nasu *et al*. 1998\[[@ref20]\]            T2NxMx                                                En bloc tumor resection with frontal craniotomy and RT                                                      Sella turcica to the subdural spaces of the right temporal lobe                                 AOD at 2 years
  Katz *et al*. 1996\[[@ref2]\]             T4aN0M0                                               Frontotemporal craniotomy, en bloc orbitectomy, and RT                                                      Nil                                                                                             AOD at 0.8 years

AOD=Alive without disease, AWD=Alive with disease, CT=Chemotherapy, DO=Died of other cause, DWD=Died with disease, LN=Lymph node, NA=Not available, Nil=No evidence of metastasis, RT=Radiotherapy

Conclusions {#sec1-4}
===========

Primary ductal adenocarcinoma of lacrimal gland is a high-grade epithelial tumor similar to salivary ductal carcinomas. Early and timely diagnosis and management and long-term follow-up are required for this aggressive tumor.

Declaration of patient consent {#sec2-3}
------------------------------

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship {#sec2-4}
---------------------------------

Nil.

Conflicts of interest {#sec2-5}
---------------------

The authors declare that there are no conflicts of interests of this paper.
